Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2026)

Entrada Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $254000.0 for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 15.61% year-over-year to $254000.0; the TTM figure through Mar 2026 stood at $254000.0 (down 15.61% YoY), while the FY2025 annual figure was $342000.0, down 97.5% from the prior year.
• Current Deferred Revenue was $254000.0 for Q1 2026 at Entrada Therapeutics, down from $342000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $148.4 million in Q3 2023 to a low of $113000.0 in Q3 2025.
• Historically, Current Deferred Revenue has averaged $35.4 million across 4 years, with a median of $9.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue jumped 76.98% in 2024, then plunged 99.75% in 2025.
• A 4-year view of Current Deferred Revenue shows it stood at $7.7 million in 2023, then surged by 76.98% to $13.7 million in 2024, then sank by 97.5% to $342000.0 in 2025, then declined by 25.73% to $254000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $254000.0 (Q1 2026), $342000.0 (Q4 2025), and $113000.0 (Q3 2025), per Business Quant data.